// App-Quantinova.ai

P991 : IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB

Researchers

Presenter

  • Patrick Harrington

Principal Investigators

  • Richard Dillon

  • Deepti Radia

  • Donal McLornan

  • Natalia Curto-Garcia

  • Claire Woodley

  • Shahram Kordasti

  • Claire Harrison

  • Hugues de Lavallade

Medical Centers

  • Guy's and St Thomas' NHS Foundation Trust,London,Reino Unido

  • Clinical Haematology &amp

  • St Thomas' NHS Foundation Trust,London,Vereinigtes Königreich

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Guy's and St Thomas' NHS Foundation Trust,London,Royaume-uni

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital,London,Royaume-uni

  • St Thomas' NHS Foundation Trust,London,Vereinigtes Königreich

  • Clinical Haematology &amp

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelofibrosis

Biomarkers

  • Natural Killer cells

  • Interleukin 2 Receptor Subunit Alpha

  • Cluster of Differentiation 4

  • Forkhead Box P3

  • Signal transducer and activator of transcription 5

  • Regulatory T cells

  • T-cell receptor

Drug/Treatment

  • Ruxolitinib phosphate

  • ZAP70

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved